← Back to Search

Cannabinoid

CBD for 8 weeks for Alcoholism

Phase 1 & 2
Waitlist Available
Led By Michael Bogenschutz, PhD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 9
Awards & highlights

Study Summary

This trial is testing whether cannabidiol (CBD) can help people with severe alcohol use disorder. It is a double-blind, randomized study, which means that neither the participants nor the researchers will know who is receiving CBD and who is receiving placebo until the study is over. The study will last for 8 weeks, and participants will be assessed at several points during and after the study.

Eligible Conditions
  • Alcoholism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 9
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 9 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Peak CBD Plasma Levels
Trough CBD Plasma Levels
Secondary outcome measures
Beck Anxiety Inventory (BAI) Score
Beck Depression Inventory (BDI) Score
Number of Drinks Per Day
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Placebo for 4 weeks, followed by phytocannabinoid cannabidiol (CBD) for 4 weeksExperimental Treatment1 Intervention
600mg/day Saline taken by mouth (PO) for 4 weeks, immediately followed by 1200mg saline/ day (PO) for an additional 4 weeks (8 total weeks).
Group II: CBD for 8 weeksExperimental Treatment1 Intervention
600mg CBD/day (PO) for 4 weeks, immediately followed by 1200mg CBD/day (PO) for an additional 4 weeks (8 total weeks).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Phytocannabinoid cannabidiol (CBD)
2019
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,369 Previous Clinical Trials
840,571 Total Patients Enrolled
11 Trials studying Alcoholism
1,429 Patients Enrolled for Alcoholism
National Institutes of Health (NIH)NIH
2,701 Previous Clinical Trials
7,506,823 Total Patients Enrolled
29 Trials studying Alcoholism
6,974 Patients Enrolled for Alcoholism
TilrayIndustry Sponsor
7 Previous Clinical Trials
218 Total Patients Enrolled
1 Trials studying Alcoholism
95 Patients Enrolled for Alcoholism

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effects of Cannabidiol in Alcohol Use Disorder
2019. "Effects of Cannabidiol in Alcohol Use Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03252756.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top